The short answer
Novo Nordisk advanced amycretin, a unimolecular GLP-1 and amylin receptor agonist, into Phase 3 development in 2026 for both subcutaneous and oral formulations. The supporting subcutaneous data was a phase 1b/2a randomised study published in the Lancet in July 2025.
Key facts
- Compound
- Amycretin, Novo Nordisk
- Class
- Unimolecular GLP-1 + amylin receptor agonist
- Formulations
- Subcutaneous and oral
- Supporting study
- Phase 1b/2a, Lancet 2025 (PMID 40550231)
- Phase 3 start
- 2026, obesity and type 2 diabetes
- Contrast
- CagriSema combines two molecules
What amycretin is
One molecule engaging both the GLP-1 receptor and the amylin receptor. That distinguishes it from CagriSema, which achieves a similar combination by pairing cagrilintide with semaglutide as two separate molecules in one injection. Amycretin is the single-molecule approach to the same pharmacological pairing.
Why the single-molecule route is pursued
One pharmacokinetic profile. Two separate agents each have their own absorption, distribution and clearance, and keeping them matched is a real formulation problem. A single molecule cannot fall out of step with itself. The same argument that motivates the multi-agonist incretins.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the published evidence was
Dahl and colleagues reported a phase 1b/2a randomised controlled study of subcutaneous amycretin in the Lancet in July 2025. Phase 1b/2a is early: the questions are safety, tolerability, pharmacokinetics and initial signals of activity, in small numbers over short durations.
What advancing to Phase 3 does and does not indicate
It indicates a sponsor's commercial and scientific judgement that the early data justifies a very large investment. It does not indicate efficacy has been established. That is what Phase 3 exists to test. Compounds enter Phase 3 and fail there routinely, and the danuglipron programme shows that even meeting objectives does not guarantee continuation.
Why the oral formulation is the more interesting half
An orally available peptide is a much harder problem than an oral small molecule, because peptides are digested. Oral semaglutide solves it with an absorption enhancer and strict administration conditions. Whether amycretin's oral form performs adequately in Phase 3 is a more open question than the subcutaneous form's.
What this does not concern
Amycretin is investigational and holds no marketing authorisation anywhere. It is not available outside registered clinical trials, and no research material is related to it or is an alternative to it.
Frequently asked questions
How does amycretin differ from CagriSema?
Amycretin is one molecule engaging both receptors. CagriSema combines two separate molecules, cagrilintide and semaglutide, in one injection.
What evidence supported the move to Phase 3?
A phase 1b/2a randomised study of the subcutaneous form published in the Lancet in July 2025, early-stage data on safety, tolerability and initial activity.
Does entering Phase 3 mean it works?
No. Phase 3 exists to test that. Compounds enter and fail there routinely.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDahl K et al., Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: phase 1b/2a. Lancet 2025 (PMID 40550231)pubmed.ncbi.nlm.nih.gov
- RefNovo Nordisk: amycretin advances to phase 3 clinical developmentnovonordisk.com
- PubMedRosenstock J et al., aleniglipron phase 2b. Nat Med 2026 (PMID 42249138)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- REDEFINE 4: The Head-to-Head Novo Nordisk Lost809 adults, 84 weeks, open-label. CagriSema reached 23.0% against tirzepatide's 25.5% and did not meet its non-inferiority endpoint.
- CagriSema After REDEFINE 4A failed head-to-head does not block an approval. What regulators actually assess, and what changed for CagriSema in February 2026.
- Searching a Trial Name Often Finds the Wrong TrialREDEFINE 4 has no acronym in ClinicalTrials.gov - searching for it returns REDEFINE 1, 2 and 3. How to find and check a registration properly.
- Accelerated Approval Is a Conditional StatementApproval on a surrogate endpoint, with confirmatory evidence required afterwards. Why that is a genuinely different decision from a standard approval.
- What the MHRA Found in a Northampton WarehouseOctober 2025: tens of thousands of empty pens, raw ingredients and over 2,000 unlicensed retatrutide and tirzepatide pens ready for dispatch.